Some Comments on the Use of Human Cells for Estimates of Risk

  • Colin F. Arlett


The credibility of estimates of risk can be placed in context by the essentially pessimistic but nevertheless realistic comments of others. Auerbach [1] in reviewing the difficulties of determining genetic hazards concluded that:

“The estimation of risk is a dangerous procedure because it will create the impression that our conclusions are meaningful, whereas in reality they are so full of uncertainties as to be practically meaningless.”


Xeroderma Pigmentosum Familial Polyposis Coli Autosomal Recessive Condition Chromosome Fragility Xeroderma Pigmentosum Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. Auerbach, The effects of six years of mutagen testing on our attitude to the problems posed by it, Mutation Res., 33: 3 (1975).Google Scholar
  2. 2.
    R. B. Cumming, Is risk assessment a Science?, Risk Analysis, 1: 1 (1981).CrossRefGoogle Scholar
  3. 3.
    M. Lesch and W. L. Nyhan, A familial disorder to uric acid metabolism and central nervous system function, Am. J. Med., 36:561 (1964).PubMedCrossRefGoogle Scholar
  4. 4.
    W. L. Nyhan, J. Pesek, L. Sweetman, D. G. Carpenter, and C. H. Carter, Genetics of an X-linked disorder of uric acid metabolism and cerebral function, Pediat. Res., 1:5 (1967).CrossRefGoogle Scholar
  5. 5.
    J. E. Seegmiller, F. M. Rosenbloom, and W. N. Kelley, Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis, Science, 155: 1682 (1967).Google Scholar
  6. 6.
    W. N. Kelley, Hypoxanthine-guanine phosphoribosyl transferase deficiency in the Lesch-Nyhan syndrome and gout, Fed. Proc., 27:1047 (1968).Google Scholar
  7. 7.
    M. F. Lyon, Sex chromatin and gene action in the mammalian X-chromosome, Am. J. Hum. Genet., 14:135 (1962).PubMedGoogle Scholar
  8. 8.
    V. A. McKusick, Mendelian Inheritance in Man, Catalogs of Autosomal Dominant, Autosomal Recessive, and X-linked Phenotypes, John Hopkins Univ. Press, Baltimore-London (1975).Google Scholar
  9. 9.
    K. H. Kraemer, Xeroderma pigmentosum, in: “Clinical Dermatology,” D. J. Dennis, R. L. Dobson, and J. McGuire, eds., (Unit 19.7: Vol. 4 ), Harper and Row, Hagerstown (1980).Google Scholar
  10. 10.
    H. Takebe, Y. Miki, T. Kozuka, J.-I. Furuyama, K. Tanaka, M. S. Sasaki, Y. Fujiwara, and H. Akiba, DNA repair characteristics and skin cancers of xeroderma pigmentosum patients in Japan, Cancer Res., 37: 490 (1977).Google Scholar
  11. 11.
    J. E. Cleaver, Defective repair replication of DNA in xeroderma pigmentosum, Nature, 218: 652 (1968).Google Scholar
  12. 12.
    A. R. Lehmann, S. Kirk-Bell, C. F. Arlett, M. C. Paterson, P. H. M. Lohman, E. A. de Weerd-Kastelein, and D. Bootsma, Xeroderma pigmentosum cells with normal levels of excision repair have a defect in DNA synthesis after UV-irradiation, Proc. Natl. Acad. Sci., USA, 72:219 (1975).PubMedCrossRefGoogle Scholar
  13. 13.
    C. A. Ramsy, T. M. Coltart, S. Blunt, S. A. Pawsey, and F. Giannelli, Prenatal diagnosis of xeroderma pigmentosum, Lancet, 2: 1109 (1974).Google Scholar
  14. 14.
    M. Swift, Malignant disease in heterozygous carriers, Birth Defects, Orig. Artic. Ser., X11: 133 (1976).Google Scholar
  15. 15.
    D. G. Harnden and B. A. Bridges, Ataxia-telangiectasia (A-T) - a model of cancer susceptibility, in: “Ataxia-telangiectasia - a cellular and molecular link between cancer, neuropathology and immune deficiency,” B. A. Bridges and D. G. Harnden, eds., John Wiley and Sons, London (1981).Google Scholar
  16. 16.
    F. Giannelli, J. A. Avery, M. E. Pembrey, and S. Blunt, Prenatal exclusion of ataxia-telangiectasia, in: Ataxia-telangiectasia - a cellular and molecular link between cancer, neuropathology and immune deficiency,“ B. A. Bridges and D. G. Harnden, eds., John Wiley and Sons, London (1981).Google Scholar
  17. 17.
    C. F. Arlett and S. A. Harcourt, Survey of radiosensitivity in a variety of human cell strains, Cancer Res., 40: 926 (1980).Google Scholar
  18. 18.
    P. R. Vessie, On the transmission of Huntington’s chorea for 300 years: The Bures family group, J. of Nerv. and Ment. Dis., 76:553 (1932).Google Scholar
  19. 19.
    E. D. Bird, A. J. Caro, and J. B. Billing, A sex related factor in the inheritance of Huntington’s chorea, Ann. of Human Genet., 37: 255 (1974).Google Scholar
  20. 20.
    C. F. Arlett and W. J. Muriel, Radiosensitivity in Huntington’s chorea cell strains: a possible pre-clinical diagnosis, Heredity, 42: 276 (1979).Google Scholar
  21. 21.
    C. F. Arlett, Presymptomatic diagnosis of Huntington’s disease, Lancet, i: 540 (1980).Google Scholar
  22. 22.
    D. A. Scudiero, S. A. Meyer, B. E. Clatterbuck, R. E. Tarone, and J. H. Robbins, Hypersensitivity to N-methyl-N’-nitro-Nnitrosoguanidine in fibroblasts from patients with Huntington’s disease, familial dysautonia, and other primary neuronal degenerations, Proc. Natl. Acad. Sci. USA, 78:6451 (1981).Google Scholar
  23. 23.
    I. A. Teo and C. F. Arlett, The response of a variety of human fibroblast cell strains to the lethal effects of alkylating agents, Carcinogenesis (in press).Google Scholar
  24. 24.
    T. Muto, H. J. R. Bussey, and B. C. Morson, The evolution of cancer of the colon and rectum, Cancer, 36: 2251 (1975).Google Scholar
  25. 25.
    B. A. Bridges, An estimate of genetic risk from 8-methoxypsoralen photochemotheraphy, Human Genet., 49: 91 (1979).Google Scholar
  26. 26.
    S. Igali, B. A. Bridges, M. J. Ashwood-Smith, and B. R. Scott, Mutagenesis in E. coli IV. Photosensitization to near ultraviolet light by 8-methoxypsoralen, Mutation Res., 9: 21 (1970).Google Scholar
  27. 27.
    B. A. Bridges and R. P. Mottershead, Frameshift mutagenesis in bacteria by 8-methoxypsoralen (methoxsalen) in the dark, Mutation Res., 44: 305 (1977).CrossRefGoogle Scholar
  28. 28.
    I. Steiner, T. Prey, F. Gschnait, J. Washiittl, and F. Greiter, Serum level profiles of 8-methoxypsoralen after oral administration, Arch. Dermatol. Res., 259:299 (1977).PubMedCrossRefGoogle Scholar
  29. 29.
    C. F. Arlett, J. A. Heddle, B. C. Broughton, and A. M. Rogers, Cell killing and mutagenesis by 8-methoxypsoralen in mammalian (rodent) cells, Clin. and Expt. Dermatol., 5:147 (1980).CrossRefGoogle Scholar
  30. 30.
    I. G. Walker and D. F. Ewart, Repair synthesis of DNA in HeLa cells and L-cells following treatment with methylnitrosourea or ultraviolet light, Can. J. Biochem., 51:148 (1973).PubMedCrossRefGoogle Scholar
  31. 31.
    H. S. Rosenkranz, E. C. McCoy, D. R. Sanders, M. Butler, K. K. Kiriazides, and R. Mermelstein, Nitropyrenes: isolation, identification and reduction of mutagenic impurities in a carbon black and toners, Science, 209: 1039 (1980).Google Scholar
  32. 32.
    C. F. Arlett, J. Cole, B. C. Broughton, J. Lowe, and B. A. Bridges, Mutagenic effects in human and mouse cells by a nitropyrene, AUI/BNL Symposium of the Genetic Effects of Air-Borne Agents (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Colin F. Arlett
    • 1
  1. 1.MRC Cell Mutation UnitUniversity of SussexFalmer, Brighton SussexEngland

Personalised recommendations